Growth hormone treatment improves final height and nutritional status of children with chronic kidney disease and growth deceleration

C. Bizzarri, A. Lonero, M. Delvecchio, L. Cavallo, M. F. Faienza, M. Giordano, L. Dello Strologo, M. Cappa

Research output: Contribution to journalArticle

Abstract

Purpose: Growth retardation is a common complication of chronic kidney disease (CKD) in children. Treatment with recombinant human growth hormone (rhGH) has been used to help short children with CKD to attain a height more in keeping with their age group, but the scientific evidence regarding the effect of rhGH on final height is scarce. Methods: Final heights of children with CKD receiving rhGH treatment (cases) were compared with final heights of a matched cohort of children with CKD that did not receive rhGH therapy (controls). Results: Sixty-eight rhGH-treated cases (44 boys) were compared with 92 untreated controls (60 boys). Mean duration of rhGH therapy was 4.2 ± 0.9 years; rhGH dose was 0.3 ± 0.07 mg/kg/week. Height SDS at baseline was lower in rhGH-treated patients than in controls (−2.00 ± 1.02 versus −0.96 ± 1.11, p < 0.001). Baseline height SDS was significantly lower than target height SDS in both groups. Height SDS significantly improved from baseline to final height attainment in rhGH-treated patients, while it slightly decreased in controls (mean SDS variation 0.69 ± 1.05 in rhGH-treated cases versus −0.15 ± 1.2 in controls). Final height SDS was −1.25 ± 1.06 in rhGH-treated cases and −1.06 ± 1.17 in controls (p = 0.29). Target adjusted final height SDS was −0.91 ± 1.03 in rhGH-treated cases and −0.61 ± 1.17 in controls (p = 0.1). Conclusions: Long-term rhGH therapy is able to reduce the linear growth deceleration of children with CKD, and ultimately to improve their final height, reducing the difference with target height.

Original languageEnglish
Pages (from-to)325-331
Number of pages7
JournalJournal of Endocrinological Investigation
Volume41
Issue number3
DOIs
Publication statusE-pub ahead of print - Aug 17 2017

Fingerprint

Deceleration
Human Growth Hormone
Nutritional Status
Chronic Renal Insufficiency
Growth Hormone
Growth
Therapeutics
Age Groups

Keywords

  • Child
  • Chronic kidney disease
  • Growth hormone
  • Height
  • Nutritional status

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Growth hormone treatment improves final height and nutritional status of children with chronic kidney disease and growth deceleration. / Bizzarri, C.; Lonero, A.; Delvecchio, M.; Cavallo, L.; Faienza, M. F.; Giordano, M.; Dello Strologo, L.; Cappa, M.

In: Journal of Endocrinological Investigation, Vol. 41, No. 3, 17.08.2017, p. 325-331.

Research output: Contribution to journalArticle

@article{036b4cd9e03d4363a9a8127f6c8a301d,
title = "Growth hormone treatment improves final height and nutritional status of children with chronic kidney disease and growth deceleration",
abstract = "Purpose: Growth retardation is a common complication of chronic kidney disease (CKD) in children. Treatment with recombinant human growth hormone (rhGH) has been used to help short children with CKD to attain a height more in keeping with their age group, but the scientific evidence regarding the effect of rhGH on final height is scarce. Methods: Final heights of children with CKD receiving rhGH treatment (cases) were compared with final heights of a matched cohort of children with CKD that did not receive rhGH therapy (controls). Results: Sixty-eight rhGH-treated cases (44 boys) were compared with 92 untreated controls (60 boys). Mean duration of rhGH therapy was 4.2 ± 0.9 years; rhGH dose was 0.3 ± 0.07 mg/kg/week. Height SDS at baseline was lower in rhGH-treated patients than in controls (−2.00 ± 1.02 versus −0.96 ± 1.11, p < 0.001). Baseline height SDS was significantly lower than target height SDS in both groups. Height SDS significantly improved from baseline to final height attainment in rhGH-treated patients, while it slightly decreased in controls (mean SDS variation 0.69 ± 1.05 in rhGH-treated cases versus −0.15 ± 1.2 in controls). Final height SDS was −1.25 ± 1.06 in rhGH-treated cases and −1.06 ± 1.17 in controls (p = 0.29). Target adjusted final height SDS was −0.91 ± 1.03 in rhGH-treated cases and −0.61 ± 1.17 in controls (p = 0.1). Conclusions: Long-term rhGH therapy is able to reduce the linear growth deceleration of children with CKD, and ultimately to improve their final height, reducing the difference with target height.",
keywords = "Child, Chronic kidney disease, Growth hormone, Height, Nutritional status",
author = "C. Bizzarri and A. Lonero and M. Delvecchio and L. Cavallo and Faienza, {M. F.} and M. Giordano and {Dello Strologo}, L. and M. Cappa",
year = "2017",
month = "8",
day = "17",
doi = "10.1007/s40618-017-0745-4",
language = "English",
volume = "41",
pages = "325--331",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "3",

}

TY - JOUR

T1 - Growth hormone treatment improves final height and nutritional status of children with chronic kidney disease and growth deceleration

AU - Bizzarri, C.

AU - Lonero, A.

AU - Delvecchio, M.

AU - Cavallo, L.

AU - Faienza, M. F.

AU - Giordano, M.

AU - Dello Strologo, L.

AU - Cappa, M.

PY - 2017/8/17

Y1 - 2017/8/17

N2 - Purpose: Growth retardation is a common complication of chronic kidney disease (CKD) in children. Treatment with recombinant human growth hormone (rhGH) has been used to help short children with CKD to attain a height more in keeping with their age group, but the scientific evidence regarding the effect of rhGH on final height is scarce. Methods: Final heights of children with CKD receiving rhGH treatment (cases) were compared with final heights of a matched cohort of children with CKD that did not receive rhGH therapy (controls). Results: Sixty-eight rhGH-treated cases (44 boys) were compared with 92 untreated controls (60 boys). Mean duration of rhGH therapy was 4.2 ± 0.9 years; rhGH dose was 0.3 ± 0.07 mg/kg/week. Height SDS at baseline was lower in rhGH-treated patients than in controls (−2.00 ± 1.02 versus −0.96 ± 1.11, p < 0.001). Baseline height SDS was significantly lower than target height SDS in both groups. Height SDS significantly improved from baseline to final height attainment in rhGH-treated patients, while it slightly decreased in controls (mean SDS variation 0.69 ± 1.05 in rhGH-treated cases versus −0.15 ± 1.2 in controls). Final height SDS was −1.25 ± 1.06 in rhGH-treated cases and −1.06 ± 1.17 in controls (p = 0.29). Target adjusted final height SDS was −0.91 ± 1.03 in rhGH-treated cases and −0.61 ± 1.17 in controls (p = 0.1). Conclusions: Long-term rhGH therapy is able to reduce the linear growth deceleration of children with CKD, and ultimately to improve their final height, reducing the difference with target height.

AB - Purpose: Growth retardation is a common complication of chronic kidney disease (CKD) in children. Treatment with recombinant human growth hormone (rhGH) has been used to help short children with CKD to attain a height more in keeping with their age group, but the scientific evidence regarding the effect of rhGH on final height is scarce. Methods: Final heights of children with CKD receiving rhGH treatment (cases) were compared with final heights of a matched cohort of children with CKD that did not receive rhGH therapy (controls). Results: Sixty-eight rhGH-treated cases (44 boys) were compared with 92 untreated controls (60 boys). Mean duration of rhGH therapy was 4.2 ± 0.9 years; rhGH dose was 0.3 ± 0.07 mg/kg/week. Height SDS at baseline was lower in rhGH-treated patients than in controls (−2.00 ± 1.02 versus −0.96 ± 1.11, p < 0.001). Baseline height SDS was significantly lower than target height SDS in both groups. Height SDS significantly improved from baseline to final height attainment in rhGH-treated patients, while it slightly decreased in controls (mean SDS variation 0.69 ± 1.05 in rhGH-treated cases versus −0.15 ± 1.2 in controls). Final height SDS was −1.25 ± 1.06 in rhGH-treated cases and −1.06 ± 1.17 in controls (p = 0.29). Target adjusted final height SDS was −0.91 ± 1.03 in rhGH-treated cases and −0.61 ± 1.17 in controls (p = 0.1). Conclusions: Long-term rhGH therapy is able to reduce the linear growth deceleration of children with CKD, and ultimately to improve their final height, reducing the difference with target height.

KW - Child

KW - Chronic kidney disease

KW - Growth hormone

KW - Height

KW - Nutritional status

UR - http://www.scopus.com/inward/record.url?scp=85027853306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027853306&partnerID=8YFLogxK

U2 - 10.1007/s40618-017-0745-4

DO - 10.1007/s40618-017-0745-4

M3 - Article

AN - SCOPUS:85027853306

VL - 41

SP - 325

EP - 331

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 3

ER -